Ramiro Guerrero Acquires 11,899 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero purchased 11,899 shares of the firm’s stock in a transaction on Thursday, August 20th. The stock was bought at an average price of $1.37 per share, for a total transaction of $16,301.63. Following the purchase, the director owned 600,117 shares in the company, valued at approximately $822,160.29. This represents a 2.02% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

MAIA Biotechnology Price Performance

Shares of MAIA stock traded down $0.04 during trading hours on Monday, hitting $1.35. The stock had a trading volume of 227,366 shares, compared to its average volume of 804,487. The stock has a market capitalization of $82.12 million, a price-to-earnings ratio of -2.18 and a beta of 0.24. MAIA Biotechnology, Inc. has a one year low of $0.87 and a one year high of $3.19. The stock’s 50-day moving average price is $1.37 and its two-hundred day moving average price is $1.46.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, equities research analysts predict that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.

Institutional Trading of MAIA Biotechnology

A number of large investors have recently made changes to their positions in the business. Marshall Wace LLP purchased a new stake in MAIA Biotechnology during the 2nd quarter valued at $29,000. Jane Street Group LLC purchased a new stake in shares of MAIA Biotechnology in the second quarter valued at $52,000. PVG Asset Management Corp bought a new stake in shares of MAIA Biotechnology in the 1st quarter worth about $46,000. Susquehanna International Group LLP purchased a new position in shares of MAIA Biotechnology during the 2nd quarter worth about $51,000. Finally, Corsair Capital Management L.P. bought a new stake in MAIA Biotechnology in the first quarter worth about $140,000. 5.65% of the stock is currently owned by institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.